<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>领星GenomiCare | wechat-feeds</title><link>http://MzI1NTQ2ODc0Mg.favicon.privacyhide.com/favicon.ico</link><description>领星是由中美生物医学数据科学家携手高年资肿瘤专家共同开创的临床科技和数据平台，提供肿瘤精准医疗和数据智能服务。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 16 Jun 2021 15:21:16 +0800</pubDate><image><url>http://MzI1NTQ2ODc0Mg.favicon.privacyhide.com/favicon.ico</url><title>领星GenomiCare | wechat-feeds</title><link>http://MzI1NTQ2ODc0Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>临床试验丨 胆管癌（四）</title><link>https://mp.weixin.qq.com/s/Tk70KP_iAjVANaz9zlvd6w</link><description></description><content:encoded><![CDATA[临床试验丨 胆管癌（四）]]></content:encoded><pubDate>Wed, 16 Jun 2021 11:34:38 +0800</pubDate></item><item><title>JAMA Oncol丨新的双免疫药物组合一线治疗转移性NSCLC</title><link>https://mp.weixin.qq.com/s/7o9agAT897Rc9c1jrMF2YA</link><description></description><content:encoded><![CDATA[JAMA Oncol丨新的双免疫药物组合一线治疗转移性NSCLC]]></content:encoded><pubDate>Tue, 15 Jun 2021 11:19:31 +0800</pubDate></item><item><title>速递丨勤浩医药获得在中国的首个IND批件；Cell：多种癌症类型普遍拥有“拼凑”式肿瘤</title><link>https://mp.weixin.qq.com/s/CzvV20zx8wb05hkuYIZi8g</link><description></description><content:encoded><![CDATA[速递丨勤浩医药获得在中国的首个IND批件；Cell：多种癌症类型普遍拥有“拼凑”式肿瘤]]></content:encoded><pubDate>Tue, 15 Jun 2021 11:19:31 +0800</pubDate></item><item><title>端午，安康！</title><link>https://mp.weixin.qq.com/s/GnI_FUv7YG-wdI0g-BqznA</link><description></description><content:encoded><![CDATA[端午，安康！]]></content:encoded><pubDate>Mon, 14 Jun 2021 09:41:56 +0800</pubDate></item><item><title>一文读懂 | NGS基因检测对肿瘤患者的意义</title><link>https://mp.weixin.qq.com/s/KcLI3RfU_Uk4OZkVQRjINA</link><description></description><content:encoded><![CDATA[一文读懂 | NGS基因检测对肿瘤患者的意义]]></content:encoded><pubDate>Thu, 10 Jun 2021 13:56:40 +0800</pubDate></item><item><title>速递丨两款国产抗肿瘤1类新药获批上市</title><link>https://mp.weixin.qq.com/s/6Vnv43vkIedZju3R75kR_g</link><description></description><content:encoded><![CDATA[速递丨两款国产抗肿瘤1类新药获批上市]]></content:encoded><pubDate>Thu, 10 Jun 2021 13:56:40 +0800</pubDate></item><item><title>临床试验丨 胆管癌（三）</title><link>https://mp.weixin.qq.com/s/SKw1LFB44VkZTerhx5_-KQ</link><description></description><content:encoded><![CDATA[临床试验丨 胆管癌（三）]]></content:encoded><pubDate>Wed, 09 Jun 2021 11:30:06 +0800</pubDate></item><item><title>最新研究进展丨可切除HCC患者的新辅助治疗手段可能是？</title><link>https://mp.weixin.qq.com/s/SVJMxgXSVy2M4CwY9Y-4Xg</link><description></description><content:encoded><![CDATA[最新研究进展丨可切除HCC患者的新辅助治疗手段可能是？]]></content:encoded><pubDate>Tue, 08 Jun 2021 11:33:51 +0800</pubDate></item><item><title>速递丨百济神州PD-1新适应症上市申请获受理；百时美施贵宝Opdivo+Yervoy组合获欧盟批准</title><link>https://mp.weixin.qq.com/s/eD_mlf2kFnPJ3cjw6PtClg</link><description></description><content:encoded><![CDATA[速递丨百济神州PD-1新适应症上市申请获受理；百时美施贵宝Opdivo+Yervoy组合获欧盟批准]]></content:encoded><pubDate>Tue, 08 Jun 2021 11:33:51 +0800</pubDate></item><item><title>星闻丨领星医学同时满分通过国家卫健委和江苏临检中心室间质评！</title><link>https://mp.weixin.qq.com/s/OeevFvpku37_TPm5-vStkA</link><description></description><content:encoded><![CDATA[星闻丨领星医学同时满分通过国家卫健委和江苏临检中心室间质评！]]></content:encoded><pubDate>Fri, 04 Jun 2021 15:54:53 +0800</pubDate></item><item><title>新一代免疫疗法突破口在哪？| 38种新靶点临床试验结果汇总</title><link>https://mp.weixin.qq.com/s/N4jHrNJ4nl6M0sbv6VV2yw</link><description></description><content:encoded><![CDATA[新一代免疫疗法突破口在哪？| 38种新靶点临床试验结果汇总]]></content:encoded><pubDate>Thu, 03 Jun 2021 11:45:49 +0800</pubDate></item><item><title>速递丨FDA批准安进Lumakras：全球首个KRAS靶向疗法!</title><link>https://mp.weixin.qq.com/s/OSulud67gjKzNe1Y9DgSeA</link><description></description><content:encoded><![CDATA[速递丨FDA批准安进Lumakras：全球首个KRAS靶向疗法!]]></content:encoded><pubDate>Thu, 03 Jun 2021 11:45:49 +0800</pubDate></item><item><title>临床试验丨 胆管癌（二）</title><link>https://mp.weixin.qq.com/s/kY79RJ_VkvMOsjcqccz5vw</link><description></description><content:encoded><![CDATA[临床试验丨 胆管癌（二）]]></content:encoded><pubDate>Wed, 02 Jun 2021 10:37:34 +0800</pubDate></item><item><title>不可切除肝细胞癌一线治疗的新标准可能是……</title><link>https://mp.weixin.qq.com/s/tJTWaUtvJdC_4Sq9FsfY4Q</link><description></description><content:encoded><![CDATA[不可切除肝细胞癌一线治疗的新标准可能是……]]></content:encoded><pubDate>Tue, 01 Jun 2021 15:42:35 +0800</pubDate></item><item><title>速递丨一线鳞状NSCLC！信达PD-1第3个适应症即将获批</title><link>https://mp.weixin.qq.com/s/ZpzzF_P-MLjB6vVkajUECA</link><description></description><content:encoded><![CDATA[速递丨一线鳞状NSCLC！信达PD-1第3个适应症即将获批]]></content:encoded><pubDate>Tue, 01 Jun 2021 15:42:35 +0800</pubDate></item></channel></rss>